23:57 GMT [Dow Jones] Bell Potter says Circadian Technologies...

23:57 GMT [Dow Jones] Bell Potter says Circadian Technologies (CIR.AU), which is
focused on the development and commercialization of angiogenesis-based therapies for the
treatment of eye diseases, has the look of a clear winner among healthcare stocks. The
company's lead asset is OPT-302, which is targeting wet age-related macular
degeneration--or wet AMD--that is the leading cause of vision impairment in the elderly.
Bell Potter, which initiates coverage of Circadian Technologies at buy with a
A$0.38/share price target, says a paucity of drugs to treat wet AMD means the market is
largely untapped. Globally, two anti-VEGF-A therapies accounted for US$7 billion in
revenue last year. "Our research indicates that the industry is receptive to a
combination approach with anti-VEGF-A therapy in wet AMD and sees multi-billion dollar
potential in it," analyst Tanushree Jain says. CIR last traded at A$0.20.
([email protected]; @dwinningWSJ)

  (END) Dow Jones Newswires
  September 10, 2015 19:57 ET (23:57 GMT)
  Copyright (c) 2015 Dow Jones & Company, Inc.
Friday 11 September 2015 09:57:00.000 AEST